ArticleThe journal of headache and pain2024
Post-marketing safety concerns with rimegepant based on a pharmacovigilance study.
Jia-Ling Hu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
15 papers cite it
this paperpooled itcites it